Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
暂无分享,去创建一个
Jilly F. Evans | R. Chopra | P. Schafer | D. Stirling | G. Muller | H. Brady | P. Schafer | J. Evans | H. Man | Dorota Cedzik | L. Capone | A. Parton | D. Cedzik | Man Hon Wah
[1] A. Gottlieb,et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. , 2013, Journal of drugs in dermatology : JDD.
[2] G. Schett,et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. , 2012, Arthritis and rheumatism.
[3] K. Papp,et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial , 2012, The Lancet.
[4] P. Haslett,et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. , 2012, The Journal of allergy and clinical immunology.
[5] P. Schafer. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. , 2012, Biochemical Pharmacology.
[6] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[7] M. Abdollahi,et al. Phosphodiesterase inhibitors in inflammatory bowel disease , 2012, Expert opinion on investigational drugs.
[8] T. Palmer,et al. Unbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3. , 2012, Biochemical Society transactions.
[9] J. Corbin,et al. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.
[10] A. Hatzelmann,et al. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. , 2011, Handbook of experimental pharmacology.
[11] M. Feldmann,et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis , 2010, Arthritis research & therapy.
[12] N. J. Eungdamrong,et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. , 2010, The Journal of allergy and clinical immunology.
[13] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[14] Lei Wu,et al. Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British Journal of Pharmacology.
[15] M. Houslay. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.
[16] A. Gottlieb,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. , 2009, Journal of the American Academy of Dermatology.
[17] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[18] P. Schafer,et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. , 2009, Journal of medicinal chemistry.
[19] M. Pal,et al. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.
[20] T. Tedder,et al. Regulatory B cells as inhibitors of immune responses and inflammation , 2008, Immunological reviews.
[21] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[22] B. Strober,et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast* , 2008 .
[23] D. Aronoff,et al. Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.
[24] J. Beavo,et al. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.
[25] G. Baillie,et al. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. , 2007, Circulation research.
[26] James G. Krueger,et al. Pathogenesis and therapy of psoriasis , 2007, Nature.
[27] G. Baillie,et al. cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. , 2006, Biochemical Society transactions.
[28] Kam Y. J. Zhang,et al. Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.
[29] K. Vranizan,et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] G. Baillie,et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[31] G. Molostvov,et al. The effects of selective cytokine inhibitory drugs (CC‐10004 and CC‐1088) on VEGF and IL‐6 expression and apoptosis in myeloma and endothelial cell co‐cultures , 2004, British journal of haematology.
[32] K. Smith,et al. Tracking antigen-specific lymphocytes in vivo. , 2004, Methods in molecular biology.
[33] T. Okamoto,et al. Inhibition of the NF-κB transcriptional activity by protein kinase A , 2002 .
[34] M. Fresno,et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.
[35] M. Saraste,et al. FEBS Lett , 2000 .
[36] A. Olsen,et al. Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. , 1999, Cellular signalling.
[37] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.
[38] L. Corral,et al. Thalidomide analogs and PDE4 inhibition. , 1998, Bioorganic & medicinal chemistry letters.
[39] A. Olsen,et al. Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. , 1998, The Biochemical journal.
[40] N. Mackman,et al. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. , 1997, Journal of immunology.
[41] M. Conti,et al. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. , 1997, Molecular pharmacology.
[42] Nigel Mackman,et al. Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells* , 1996, The Journal of Biological Chemistry.
[43] M. Conti,et al. Identification of cyclic AMP‐phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells , 1996, FEBS letters.
[44] M. Mclaughlin,et al. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. , 1993, The Journal of biological chemistry.